Treatment of multiple sclerosis with T-cell receptor peptides: Results of a double-blind pilot trial

Arthur A. Vandenbark; Yuan K. Chou; Ruth Whitham; Michele Mass; Abigail Buenafe; Diane Liefeld; Daniel Kavanagh; Shelley Cooper; George A. Hashim; Halina Offner; Dennis N. Bourdette

doi:10.1038/nm1096-1109

Treatment of multiple sclerosis with T-cell receptor peptides: Results of a double-blind pilot trial

Arthur A. Vandenbark, Yuan K. Chou, Ruth Whitham, Michele Mass, Abigail Buenafe, Diane Liefeld, Daniel Kavanagh, Shelley Cooper, George A. Hashim, Halina Offner, Dennis N. Bourdette

Research output: Contribution to journal › Article › peer-review

183 Scopus citations

Abstract

A T-cell receptor (TCR) peptide vaccine from the Vβ5.2 sequence expressed in multiple sclerosis (MS) plaques and on myelin basic protein (MBP)-specific T cells boosted peptide-reactive T cells in patients with progressive MS. Vaccine responders had a reduced MBP response and remained clinically stable without side effects during one year of therapy, whereas nonresponders had an increased MBP response and progressed clinically. Peptide-specific T helper 2 cells directly inhibited MBP-specific T helper 1 cells in vitro through the release of interleukin-10, implicating a bystander suppression mechanism that holds promise for treatment of MS and other autoimmune diseases.

Original language	English (US)
Pages (from-to)	1109-1115
Number of pages	7
Journal	Nature medicine
Volume	2
Issue number	10
DOIs	https://doi.org/10.1038/nm1096-1109
State	Published - Oct 1996

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1038/nm1096-1109

Cite this

@article{c5d85771067749ddb26b6bc5078ceddc,

title = "Treatment of multiple sclerosis with T-cell receptor peptides: Results of a double-blind pilot trial",

abstract = "A T-cell receptor (TCR) peptide vaccine from the Vβ5.2 sequence expressed in multiple sclerosis (MS) plaques and on myelin basic protein (MBP)-specific T cells boosted peptide-reactive T cells in patients with progressive MS. Vaccine responders had a reduced MBP response and remained clinically stable without side effects during one year of therapy, whereas nonresponders had an increased MBP response and progressed clinically. Peptide-specific T helper 2 cells directly inhibited MBP-specific T helper 1 cells in vitro through the release of interleukin-10, implicating a bystander suppression mechanism that holds promise for treatment of MS and other autoimmune diseases.",

author = "Vandenbark, {Arthur A.} and Chou, {Yuan K.} and Ruth Whitham and Michele Mass and Abigail Buenafe and Diane Liefeld and Daniel Kavanagh and Shelley Cooper and Hashim, {George A.} and Halina Offner and Bourdette, {Dennis N.}",

year = "1996",

month = oct,

doi = "10.1038/nm1096-1109",

language = "English (US)",

volume = "2",

pages = "1109--1115",

journal = "Nature medicine",

issn = "1078-8956",

publisher = "Nature Publishing Group",

number = "10",

}

TY - JOUR

T1 - Treatment of multiple sclerosis with T-cell receptor peptides

T2 - Results of a double-blind pilot trial

AU - Vandenbark, Arthur A.

AU - Chou, Yuan K.

AU - Whitham, Ruth

AU - Mass, Michele

AU - Buenafe, Abigail

AU - Liefeld, Diane

AU - Kavanagh, Daniel

AU - Cooper, Shelley

AU - Hashim, George A.

AU - Offner, Halina

AU - Bourdette, Dennis N.

PY - 1996/10

Y1 - 1996/10

N2 - A T-cell receptor (TCR) peptide vaccine from the Vβ5.2 sequence expressed in multiple sclerosis (MS) plaques and on myelin basic protein (MBP)-specific T cells boosted peptide-reactive T cells in patients with progressive MS. Vaccine responders had a reduced MBP response and remained clinically stable without side effects during one year of therapy, whereas nonresponders had an increased MBP response and progressed clinically. Peptide-specific T helper 2 cells directly inhibited MBP-specific T helper 1 cells in vitro through the release of interleukin-10, implicating a bystander suppression mechanism that holds promise for treatment of MS and other autoimmune diseases.

AB - A T-cell receptor (TCR) peptide vaccine from the Vβ5.2 sequence expressed in multiple sclerosis (MS) plaques and on myelin basic protein (MBP)-specific T cells boosted peptide-reactive T cells in patients with progressive MS. Vaccine responders had a reduced MBP response and remained clinically stable without side effects during one year of therapy, whereas nonresponders had an increased MBP response and progressed clinically. Peptide-specific T helper 2 cells directly inhibited MBP-specific T helper 1 cells in vitro through the release of interleukin-10, implicating a bystander suppression mechanism that holds promise for treatment of MS and other autoimmune diseases.

UR - http://www.scopus.com/inward/record.url?scp=16044361810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16044361810&partnerID=8YFLogxK

U2 - 10.1038/nm1096-1109

DO - 10.1038/nm1096-1109

M3 - Article

C2 - 8837609

AN - SCOPUS:16044361810

SN - 1078-8956

VL - 2

SP - 1109

EP - 1115

JO - Nature medicine

JF - Nature medicine

IS - 10

ER -

Treatment of multiple sclerosis with T-cell receptor peptides: Results of a double-blind pilot trial

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this